

---

## Product Data Sheet

---

Product Name: Cycloguanil D6

Cat. No.: GC39367

### Chemical Properties

Cas. No.

SMILES C1C=CC=C(N2C(N)=NC(N)=NC2(C([2H]))([2H])[2H])C([2H])([2H])[2H])C=C1Formula  $C_{11}H_8D_6ClN_5$  M.Wt 257.75

Solubility Soluble in DMSO Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure 

### Background

Cycloguanil-d<sub>6</sub> is intended for use as an internal standard for the quantification of cycloguanil by GC- or LC-MS. Cycloguanil is the active metabolite of the antimalarial prodrug proguanil.<sup>1</sup> Cycloguanil is formed from proguanil by the cytochrome P450 (CYP) isoforms CYP2C19 and CYP3A in human liver microsomes. It is an inhibitor of dihydrofolate reductase (DHFR; K<sub>i</sub>s = 1.5 and 0.79 nM for the *P. falciparum* and *P. berghei* enzymes, respectively).<sup>2,3</sup> It is active against ten *P. falciparum* field isolates (IC<sub>50</sub>s = 0.12-1,400 µg/ml).<sup>2</sup> Cycloguanil reduces parasitemia in a mouse model of *P. berghei* infection (ED<sub>50</sub> = 2 mg/kg).<sup>4</sup> It also reduces parasitemia in a rhesus monkey model of *P. cynomolgi* infection when administered at a dose of 0.3 mg/kg.<sup>5</sup>

1. Birkett, D.J., Rees, D., Anderson, T., et al. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. *Br. J. Clin. Pharmacol.* 37(5):413-420 (1994)  
 2. Foote, S.J., Galatis, D., and Cowman, A.F. Amino acids in the dihydrofolate reductase-thymidylate synthase gene of *Plasmodium falciparum* involved in cycloguanil resistance differ from those involved in

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

---

**Product Data Sheet**

---

pyrimethamine resistance Proc. Natl. Acad. Sci. USA 87(8)3014-3017(1990) 3. Yuthavong, Y., Vilaivan, T., Chareonsethakul, N., et al. Development of a lead inhibitor for the A16V+S108T mutant of dihydrofolate reductase from the cycloguanil-resistant strain (T9/94) of Plasmodium falciparum J. Med. Chem. 43(14)2738-2744(2000) 4. Knight, D.J., and Peters, W. The antimalarial activity of N-benzyloxydihydrotriazines. I. The activity of clociguanil (BRL 50216) against rodent malaria, and studies on its mode of action Ann. Trop. Med. Parasitol. 74(4)393-404(1980) 5. Schmidt, L.H., Loo, T.L., Fradkin, R., et al. Antimalarial activities of triazine metabolites of chlorguanide and dichlorguanide Proc. Soc. Exp. Biol. Med. 80(2)367-370(1952)

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA